Mercer Global Advisors Inc. ADV bought a new position in Balchem Co. (NASDAQ:BCPC – Get Rating) during the first quarter, according to its most recent filing with the SEC. The firm bought 1,578 shares of the basic materials company's stock, valued at approximately $216,000.
A number of other large investors also recently modified their holdings of BCPC. Advisor Group Holdings Inc. lifted its holdings in shares of Balchem by 4.2% in the 4th quarter. Advisor Group Holdings Inc. now owns 5,264 shares of the basic materials company's stock worth $887,000 after purchasing an additional 211 shares in the last quarter. American Century Companies Inc. bought a new position in shares of Balchem in the 4th quarter worth $671,000. First Trust Advisors LP lifted its holdings in shares of Balchem by 87.4% in the 4th quarter. First Trust Advisors LP now owns 63,774 shares of the basic materials company's stock worth $10,752,000 after purchasing an additional 29,749 shares in the last quarter. CIBC Asset Management Inc purchased a new stake in Balchem in the 4th quarter valued at $213,000. Finally, Raymond James & Associates raised its position in Balchem by 1.1% in the 4th quarter. Raymond James & Associates now owns 38,228 shares of the basic materials company's stock valued at $6,445,000 after buying an additional 422 shares during the last quarter. 89.15% of the stock is currently owned by institutional investors.
Get Balchem alerts:Insider Activity
In other news, VP Gunsteren Job Leonard Van sold 3,601 shares of the firm's stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $125.62, for a total transaction of $452,357.62. Following the completion of the sale, the vice president now directly owns 1,430 shares of the company's stock, valued at approximately $179,636.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.60% of the company's stock.
Analyst Ratings Changes
BCPC has been the subject of a number of analyst reports. HC Wainwright increased their price target on Balchem from $152.00 to $164.00 and gave the company a "buy" rating in a research report on Monday, August 22nd. StockNews.com lowered Balchem from a "buy" rating to a "hold" rating in a research report on Monday, August 1st.Balchem Trading Down 0.9 %
Shares of Balchem stock opened at $129.20 on Friday. Balchem Co. has a 1 year low of $110.15 and a 1 year high of $174.29. The firm has a market cap of $4.15 billion, a PE ratio of 38.68 and a beta of 0.59. The stock has a fifty day moving average price of $131.41 and a 200-day moving average price of $130.21. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.62 and a quick ratio of 1.64.
Balchem Profile
(Get Rating)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Further Reading
- Get a free copy of the StockNews.com research report on Balchem (BCPC)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC – Get Rating).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.